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INTRODUCTION 
The aim of this workshop was to discuss in the broadest terms the role of blood 
vessels in establishing and maintaining a healthy pregnancy. It focused on the 
vessels at the feto/maternal interface namely the vessels of chorionic villi and the 
maternal spiral arteries. Cells of these vessels interact closely with trophoblast cells 
but with very different outcomes. In the chorionic villi this interaction must work to 
promote and maintain vessel integrity whilst the interactions between the extravillous 
trophoblasts and the cells of the maternal spiral artery lead in early pregnancy to 
vessel instability and remodelling and later vessel stabilisation. Knowledge of the 
mechanisms behind these paradoxical events may allow new therapeutic 
approaches to pregnancy complications such as placental insufficiency. The specific 
questions addressed by organisers and participants included the nature of the 
interaction between the developing chorionic vascular tree and the chorionic villous 
trophoblast stem cells, the nature of the interaction between extravillous trophoblasts 
and the cells of the maternal spiral artery specifically whether apoptosis plays a role 
in the remodelling of maternal spiral arteries. The role of traditional growth factors 
such as vascular endothelial growth factor (VEGF) in regulation of maternal and fetal 
vascular growth and vascular tone was also addressed. 
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HETEROGENEITY OF ENDOTHELIAL GENE EXPRESSION 
The heterogeneity of fetal endothelial cells per se was addressed by Bill Kalionis 
(Australia) in his talk entitled ‘Homeobox gene expression in placental microvascular 
endothelial cells’. Using a variation of the perfusion-based method described by Lang 
et al. [1] placental endothelial cells (PLEC) were isolated by perfusion of the fetal 
placental vasculature with proteolytic enzymes and enrichment of the cells by Percoll 
gradient centrifugation. Yields of 5x104 to 6x105 cells per cotyledon, with 93-98% 
purity and 66.3-100% viability, were obtained by this technique. Using RT-PCR 
analysis of uncultured PLEC, the homeobox genes DLX3, DLX4, MSX2, GAX and 
HLX1 were found to be expressed in microvascular endothelial cells. Furthermore, 
one of these homeobox genes, HLX1, was not expressed at high levels in human 
umbilical vein (HUVEC) cells indicating that the macrovascular HUVEC and 
microvascular PLEC display significant gene expression differences. Microarray 
analysis on enriched placental endothelial cells also detected expression of the 
above homeobox genes but revealed six additional homeobox genes [2] whose 
expression in PLEC were confirmed by RT-PCR. One of these homeobox genes, 
HEX, is an important regulator of endothelial cells in the cardiovascular system but 
had not been previously identified in the placenta. The remaining five homeobox 
genes, again had not previously been identified in the placenta, or in endothelial 
cells, but were shown to be expressed in embryonic cell types and tissues. Kalionis 
concluded that it was important to study gene expression on enriched cell 
populations, rather than whole placental tissue, since this approach has broadened 
the repertoire of potentially important genes in the placental vasculature. 
 
VILLOUS TROPHOBLAST - ENDOTHELIAL INTERACTIONS 
Josette Badet (France) addressed the important issue of vasculogenesis within the 
chorionic villi and whether adjacent cells may influence this. During human placental 
development, the chorionic villi grow in coordination with the establishment of a large 
capillary network that occurs by means of both vasculogenesis from in situ 
differentiating endothelial cells and angiogenesis by sprouting capillaries from pre-
existing vessels [3]. Endothelial cells differentiate into blood vessels as a result of 
signals from adjacent cells. In early placenta, vasculogenesis might be controlled by 
villous cytotrophoblast [4]. However, in different models, endothelial cells have been 
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shown to provide developmental signals to the growing organ throughout 
development [5] and might induce essential steps in organ formation, prior to blood 
vessel function [6]. Badet et al. showed that there was immunoreactivity to 
angiogenin, a potent inducer of blood vessel formation, in key points in the 
developing early chorionic villi. It has been previously shown by her group to be 
expressed in the human term placenta [7]. At this workshop, angiogenin was shown 
to be associated with actively dividing endothelial and trophoblast cells which might 
reflect cordinated morphological development. Cells and the cellular extensions that 
bridge the cytotrophoblast layer to the nascent vessels expressed endothelial 
markers and were strongly labelled for angiogenin as well as the trophoblasts facing 
them. Given the biological activities of angiogenin in vitro and the induction of 
expression in response to hypoxia recently shown by Rajashekhar and collaborators 
in placental tissue culture [8], these data suggest that angiogenin might play a role in 
placental organogenesis in concert with other regulators, and opens the discussion 
on the possibility for endothelial cells to driving or signaling placental growth and 
morphogenesis. 
 
REGULATION OF MATERNAL AND FETAL VASCULATURE BY PLACENTAL 
VEGF 
Vascular endothelial growth factor (VEGF) is a well known angiogenic growth factor 
and permeability factor. Paul Brownbill (UK) in his talk entitled ‘Placental secretion of 
VEGF into the fetal land maternal circulations’ introduced the novel concept of the 
placenta as a major regulatory organ of maternal VEGF endocrinology, as well as 
being involved as a vasodilator of fetal vessels [9] and in fetal angiogenesis [10, 11]. 
Data were presented on the measurement of (i) the summated concentrations of total 
VEGF 121 & 165 isoforms (tVEGF, RIA), (ii) the summated concentrations of all free 
isoforms of VEGF-A (fVEGF, sandwich ELISA) and (iii) the total concentrations of the 
soluble VEGFR-1 receptor (sVEGFR-1, sandwich ELISA), in fetal- and maternal-side 
venous perfusate samples from term healthy in vitro, open-circuit, superoxic-perfused 
placental lobules, and also in cord sera. tVEGF was secreted into both the fetal and 
maternal circulations during perfusion, with levels in both circulations plateauing after 
60 min. When all measured ligands were considered within all groups of perfusate 
and serum samples, there was found to be a common inverse relationship between 
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sVEGFR-1:tVEGF ratio and fVEGF levels. This relationship is in agreement with 
other studies on maternal serum [12,13]. 
Measurements of tVEGF in the fetal cord arterial and venous sera were around 
2.5 times that measured in the perfused placental lobule. (The lower fetal-side 
release in vitro might be attributable to the superoxic nature of the model, as 
currently employed). The release of all ligands into the fetal circulation was low, but 
tVEGF release exceeded sVEGFR-1 release, so that there were measurable, but 
very low levels of fVEGF in fetal venous perfusate. However, arterial cord sera levels 
of fVEGF were much higher than this, suggesting that the placenta has a relatively 
unimportant fetal endocrine role with regards to the determination of fVEGF sera 
levels. An fVEGF venous serum concentration of around 39 pM, based on the m/w of 
the VEGF-165 isoform, closely approximates to the EC50 of 45 pM found for the 
vasodilatory response of fetoplacental vasculature found in the in vitro perfused term 
healthy lobule [12]. VEGF thus is a physiologically significant regulator of 
fetoplacental tone in vivo. 
Interestingly, in these experiments, very high level of sVEGFR-1 was detected in 
the maternal-side venous perfusate, which exceeded that of high tVEGF levels, 
causing complete sequestration of VEGF, leading Brownbill et al. to conclude that the 
placenta may be a major regulatory organ of maternal VEGF endocrinology. 
Immeasurable levels of fVEGF in the maternal venous perfusate contrasts with the 
small but significant level of fVEGF in the peripheral maternal circulation [12]. This 
imbalance must be addressed in vivo by further net secretions of VEGF from other 
maternal compartments to permit bio-activity of VEGF within the maternal peripheral 
circulation and to assist in the appropriate regulation of systemic maternal vascular 
function. 
 
TROPHOBLAST – MATERNAL VESSEL INTERACTIONS 
The second part of the workshop was dedicated to talks on the invading fetal 
trophoblast cells with cells of the maternal vessels. Rosemary Keogh (UK) and Lynda 
Harris (UK) addressed the issues of ‘Vascular remodelling in pregnancy’. Keogh, 
gave an elegant summary of the main features of this interaction. Vascular 
remodelling of resistance arteries typically involves medial thickening through 
hyperplasia of smooth muscle cells (SMC) and deposition of extra-cellular matrix.  
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The result is a reduction in lumen diameter and increased resistance. In human 
pregnancy the opposite occurs when the uterine spiral arteries are remodelled. There 
is loss of both endothelium and SMC resulting in medial ablation, luminal expansion 
and a decrease in resistance. The factors that influence vessel remodelling can be 
classified as cellular, micro-environmental or genetic. In pregnancy, the cellular 
effect, namely the presence of the trophoblast, is the most important factor that 
determines the outcome of remodelling.  Due to the scarcity of appropriate tissue and 
models, little work has been done to understand the basics of spiral artery 
remodelling in human pregnancy. Recent work on pregnant rats has identified 
features that suggest they could be a useful model for future investigations into the 
fundamental mechanisms of remodelling in human pregnancy [14]. 
Shallow or incomplete trophoblast invasion with limited vessel remodelling have 
been associated with complications of human pregnancy such as pre-eclampsia. 
Work on spiral artery remodelling has focussed on defects that may lead to this 
outcome, however, little is known about the basis of remodelling in normal 
pregnancy. Data were presented by Keogh and co-workers demonstrating that 
primary cytotrophoblast can initiate SMC apoptosis in spiral arteries via the Fas/Fas 
ligand pathway [15,16]. A trophoblast-dependent apoptotic mechanism could thus 
contribute to SMC loss during remodelling. Apoptosis is a slow and gradual event, 
typically involving single cells which can take upwards of 24 hours to die following an 
initial apoptotic signal [17]. Apoptosis thus proceeds in an asynchronous manner 
leading to a cumulative effect.  This is in keeping with the time course of spiral artery 
remodelling in vivo which is a gradual process occurring  over a period of weeks. 
Many factors will affect the interactions between trophoblast and SMC. Secreted 
chemokines may attract trophoblast to SMC and recent work has identified a role for 
the eph/ephrin family in stimulating trophoblast invasion [18,19]. Placental hormones 
such as human placental lactogen and human chorionic gonadotropin (hCG) may act 
to positively or negatively regulate SMC apoptosis. hCG has been reported to both 
protect cells from apoptosis [20] and to increase apoptosis [21]. Cytokines found in 
the maternal-fetal environment can alter expression of apoptotic ligands such as 
TNF-related apoptosis-inducing ligand (TRAIL) which is produced by trophoblast and 
is up-regulated by TNFα and IFNγ stimulation [22,23]. Spiral artery remodelling in 
pregnancy thus relies on a complex coordination of micro-environmental factors, cell-
cell interactions and apoptotic events over an extended time frame that maintains 
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vessel integrity. The end result is a unique transformation of maternal vessels which 
is essential for the maintenance of a successful pregnancy. 
L. Harris (UK) provided evidence that indeed a soluble factor released by first 
trimester trophoblast initiates apoptosis of vascular smooth muscle, in the absence of 
direct cell contact. Human arterial SMC incubated with primary cytotrophoblast (CTB)-
conditioned culture medium undergo apoptosis, and this phenomenon is inhibited by 
a Fas ligand-blocking antibody. These findings were replicated in a 3-dimensional 
model of endovascular trophoblast invasion. Spiral artery segments denuded of 
endothelium were perfused with primary CTB-conditioned culture medium, in the 
presence or absence of the Fas ligand-blocking antibody. After 24h in culture, SMC 
apoptosis was assessed by TUNEL. CTB-conditioned medium pre-treated with NOK-
2 induced significantly less vascular SMC apoptosis than CTB-conditioned medium 
pre-treated with a control IgG (P<0.001, repeated measures ANOVA). In addition, 
immunohistochemistry demonstrated the presence of Fas ligand in vesicle-like 
structures within the cytoplasm of first trimester CTB. Loss of SMC during arterial 
remodelling in pregnancy involves in part, cell death triggered by soluble Fas ligand 
released by invading CTB.  
Timing of remodelling events is crucial and luminal cells are not all exposed to 
apoptotic stimuli at the same time. Interactions between CTB and SMC involve only 
a few cells in a localised microenvironment at one time. This allows remodelling to 
take place over a period of weeks, thus maintaining vessel integrity and function. 
Remodelling events may also be mediated by trophoblast-derived proteases that 
degrade the extracellular matrix. Data were presented providing evidence of first 
trimester CTB engulfing and digesting elastin fibres. The use of three-dimensional 
models of endovascular trophoblast invasion appears to be a useful advance in 
studies into how the extracellular matrix and vessel structure may influence 
remodelling events. 
 
PHENOTYPIC PLASTICITY 
As concluding remarks, Lopa Leach (UK) cautioned that although micro-
heterogeneity may be a feature of endothelial cells in vivo, this was not necessarily 
due to intrinsic and unchangeable properties of the cell. The environment itself, 
dictates the phenotype. Data were presented showing that when human umbilical 
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vein cells (HUVEC) are grown in a three-dimensional model (trilayer with HUVEC, 
amnion and retinal pigment epithelial cells) to mimic the outer retinal barrier, HUVEC 
cells do not show fidelity of origin but demonstrate a fenestrated rather than 
continuous endothelial phenotype, resembling the chorio-capillaris [24]. Localisation 
of VEGF in the trophoblast of first trimester placenta (i.e. developmental stage) and 
in the terminal villous trophoblast of third trimester placenta (i.e. functionality: conduit 
versus exchange) correlates with a dynamic junctional phenotype of angiogenic and 
exchange microvessels;  endothelial junctions here do not possess the tight 
junctional adhesion molecule occludin or plakoglobin, the adherens junctional 
molecule [11,25]. In other vascular beds, such as the rat blood-brain barrier, induced 
transitory loss of astrocytes results in reversible loss of occludin from tight junctional 
complexes and loss of barrier function [26]. Thus the cross- talk between epithelial 
and endothelial cells is important for phenotypic determination and functioning, both 
in vivo and in vitro. 
CONCLUSIONS AND FUTURE DIRECTIONS 
This workshop highlighted the need for multi-dimensional human models where 
different cell types, and their paracrine secretions are allowed to contribute to the 
final outcome of the experimental stimulus. Rather than reductionist methods alone, 
such as that provided by cell monocultures, the use of more complex ex vivo and in 
vitro models such as the extra-corporeally perfused human placenta, the co-cultures 
and trilayers may well lead the way in this complex and important field of 
development. These models will allow one to reveal how the fetal trophoblast 
influences the fate of endothelial cells – angiogenesis and stability for fetal vessels 
whilst exerting regionally defined apoptosis for maternal vessels. Greater 
collaboration and communication between scientists working on maternal spiral 
artery remodelling and chorionic villous remodelling is essential to address some of 
the important questions about trophoblast-endothelial interactions which allow 
seeming paradoxes to exist in early development of maternal and fetal circulation of 
the human placenta. 
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